CTOs on the Move

A. M. Pappas

www.ampappas.com

 
A. M. Pappas is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ampappas.com
  • 2520 Meridian Pkwy Ste 400
    Durham, NC USA 27713
  • Phone: 919.998.3300

Executives

Name Title Contact Details

Similar Companies

Aegerion

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

Knopp Neurosciences

Knopp Neurosciences is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NanoString

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company`s technology enables a wide variety of basic research and translational medicine applications. NanoString`s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

Xenotope Diagnostics

Xenotope Diagnostics is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.